Visiongain has published a new report entitled Geographic Atrophy Market Report 2024-2034: Forecasts by Type (Focal GA, Multifocal GA, Confluent GA), by Drugs (Pegcetacoplan (SYFOVRE), Avacincaptad Pegol (IZERVAY), Others), by Route of Administration (Intravitreal, Intravenous, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, E-Commerce Pharmacies) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global geographic atrophy market is estimated at US$4,570.9 million in 2024 and is projected to grow at a CAGR of 15.6% during the forecast period 2024-2034.

New Product Launches Are Driving the Market Growth

The geographic atrophy (GA) market is rapidly expanding, driven by innovative product launches and strategic commercial efforts. Notably, the FDA approved SYFOVRE (pegcetacoplan) by Apellis Pharmaceuticals on February 17, 2023, for GA due to age-related macular degeneration (AMD), with over 6,000 vials distributed within a month of its March 1, 2023 rollout. SYFOVRE, a complement inhibitor targeting C3, shows promise in slowing disease progression and has set a benchmark for other companies. Additionally, the FDA approved Izervay (avacincaptad pegol) on August 4, 2023, as the first GA treatment to significantly reduce progression over 12 months. Iveric Bio’s commercial strategy for Izervay includes partnerships with healthcare providers and educational campaigns. These strategic launches and innovative treatments are propelling GA market growth and paving the way for future advancements.

How will this Report Benefit you?

Visiongain’s 218-page report provides 80 tables and 144 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analyses for the geographic atrophy market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for Geographic Atrophy. Get financial analysis of the overall market and different segments including type, drugs, Route of Administration, and distribution channel and capture higher market share. We believe that there are strong opportunities in this fast-growing geographic atrophy market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

The Rising Prevalence of GA is Propelling Market Growth

Geographic atrophy (GA) predominantly impacts individuals aged 60 and older, marking the advanced stage of dry age-related macular degeneration (AMD) and potentially leading to irreversible retinal damage. Characterized by distinct oval or round areas of hypopigmentation at least 175 µm in diameter, GA is becoming more prevalent. A 2024 Journal of the American Medical Association (JAMA) publication forecasts a substantial increase in AMD cases globally over the next 20 years, with around 20 million people in the U.S. and 196 million worldwide currently affected, and projections indicating a rise to 288 million by 2040. The growing elderly population, fueled by increased life expectancy and declining birth rates, is a significant contributor. A 2023 United Nations report indicates that least developed countries (LDCs) predominantly feature a youthful demographic, with only 3.7 percent aged 65 or older, compared to 9 percent in other developing countries and 20 percent in developed nations.

The Rising Geriatric Population is Boosting the Demand for GA Drugs

Geographic atrophy (GA), predominantly affecting individuals aged 60 and older, marks the advanced stage of dry age-related macular degeneration (AMD) and leads to irreversible retinal damage. A 2024 Journal of the American Medical Association (JAMA) publication projects that approximately 20 million people in the U.S. and 196 million worldwide currently have AMD, with cases expected to increase to 288 million by 2040. This rise is driven by longer life expectancies and declining birth rates, contributing to a growing elderly population. According to a 2023 United Nations report, least developed countries (LDCs) currently have a youthful demographic, with only 3.7% aged 65 or older, compared to 9% in other developing countries and 20% in developed nations, but this proportion is expected to grow significantly. In developed countries like the U.S., UK, France, and Germany, about 1 in 29 individuals aged 75 and older are affected by GA.

Where are the Market Opportunities?

Increasing R&D Investments From Pharmaceutical and Biopharmaceutical Companies

Pharmaceutical and biopharmaceutical companies within the GA market are significantly increasing their R&D investments to expand their product offerings and drive market growth. These companies employ competitive strategies focusing on cost-effectiveness, product quality, reliability, and post-sales services to achieve early market entry with new treatments. In the competitive GA market, delivering cost-efficient and high-quality products is crucial for success. Local manufacturing is a primary strategy used by manufacturers to reduce operational costs and enhance market penetration. Genentech, Inc., a subsidiary of Roche Holding Ltd., is conducting clinical trials of OpRegen, a retinal pigment epithelium (RPE) cell therapy for GA. Similarly, Lineage Cell Therapeutics, Inc. announced the two-year visual acuity outcomes of its Phase 1/2a clinical study of RG6501 (OpRegen) for GA secondary to AMD on May 6, 2024. Iveric Bio, specializing in therapies for retinal conditions, disclosed novel findings on April 23, 2023, from data analyses of avacincaptad pegol (ACP), an investigational therapeutic agent targeting GA secondary to AMD. ACP, a pioneering inhibitor of complement C5 protein, showed a 56% reduction in the risk of sustained visual impairment in GA patients treated with ACP 2 mg compared to placebo during the first 12 months of treatment.

Promising Therapies for Geographic Atrophy

Several promising therapies for geographic atrophy (GA) include AVD-104, Zimura (avacincaptad pegol), ALK-001, Risuteganib, and more. The FDA accepted the New Drug Application for Zimura in February 2023, with priority review, and approved SYFOVRE (pegcetacoplan injection) for GA secondary to age-related macular degeneration (AMD) on February 17, 2023. Although NGM Bio’s CATALINA Phase II trial of NGM621 did not meet its primary endpoint, ongoing developments highlight the evolving GA treatment landscape. In August 2023, the FDA approved IZERVAY (avacincaptad pegol intravitreal solution) for GA, marking a significant advancement. IZERVAY, a complement C5 inhibitor, showed a statistically significant reduction in GA progression over 12 months in Phase 3 trials, potentially transforming GA management. The introduction of retinal gene therapies and widespread adoption of autofluorescence imaging technology further catalyse market growth.

Competitive Landscape

The major players operating in the geographic atrophy market are Alkeus Pharmaceuticals, Inc., Bausch + Lomb, Santen Pharmaceutical Co., Ltd., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Apellis Pharmaceuticals, AstraZeneca, Johnson & Johnson, and Ionis Pharmaceuticals. These major players operating in this market have adopted various strategies including investment in R&D, M&A, new product launches, and partnerships.

Recent Developments

• On 30th April 2024, CDR-Life Inc. and Boehringer Ingelheim (BI) partnered for clinical trial phase 1 of a candidate that can be used in the treatment of geographic atrophy (GA).
• On 26th March 2024, Astellas received complete permission of J-code for IZERVAY) that can be used in treating of Geographic Atrophy.

Notes for Editors

If you are interested in a more detailed overview of this report, please send an e-mail to contactus@visiongain.com or call +44 207 336 6100.

About Visiongain

Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.